대한뉴팜

Daehan New Pharm, a KOSDAQ-listed company well known for its “Luthione” and “Cindella” injection, has launched its new whitening skincare line, “Luthione Skin Care”, as part of its wellness business expansion. The newly introduced “Luthione Skin Care” is a dual-function product line that improves both whitening and wrinkle reduction. It consists of two essential base items—a lotion and a cream—with plans for further expansion of the line. Through continuous innovation in wellness and medical formulations, Daehan New Pharm has achieved remarkable results by focusing on specialization, global business expansion, and direct management of medical institutions. The company is strengthening its distribution network, diversifying its product portfolio through ongoing launches, and developing creative sales strategies by cultivating top-tier talent. The release of this cosmetic line represents the company’s initiative to apply its wellness-based pharmaceutical research expertise to cosmetics, thereby establishing a new, integrated wellness product line. One of the key ingredients in Luthione Skin Care, β-glucan, has been enhanced to achieve over 80% higher absorption compared to existing β-glucan products. Combined with glutathione and adenosine, it delivers powerful whitening and nourishing effects to the skin. As more pharmaceutical companies diversify into the cosmetics sector, Luthione Skin Care stands out for its unique formulation, clinical expertise, and proven efficacy, drawing attention as a differentiated cosmeceutical line in the market.

- Achieved 28.9% increase in sales and 24.4% increase in operating profit compared to the previous year- Confirmed receipt of the 10 Million Dollar Export Tower AwardDaehan New Pharm’s growth momentum continued through the third quarter of 2015. By the end of Q3 2015, cumulative sales reached 66.955 billion KRW, up 28.9% year-over-year, and operating profit increased by 24.4% to 7.293 billion KRW. The operating profit margin also improved to 10.9%, indicating sustained qualitative growth driven by profitability. In addition to this growth, the company reduced accounts receivable by 353 million KRW and borrowings by 1.548 billion KRW compared to the end of 2014. This led to an improvement in accounts receivable turnover days by 33.7 days and a reduction in the debt-to-sales ratio by 11.2 percentage points to 43.5%, contributing to financial stabilization. Daehan New Pharm’s strategy focuses on its mission to promote healthy lives, a happy society, and warmth by emphasizing fundamentals, strengthening core capabilities, prioritizing cash flow, proactive management, pioneering product launches, expanding distribution coverage through creative sales solutions, and talent-centered management, continuously driving value innovation. The overseas business division also recorded remarkable export growth. By developing the wellness product market in China and solidifying partnerships in Russia, the company secured the 10 Million Dollar Export Tower Award. Since beginning exports to Southeast Asia, including Vietnam, in 1999, Daehan New Pharm won the 5 Million Dollar Export Tower Award in 2007. The company exports various pharmaceuticals, including obesity treatments, to over 30 countries worldwide such as Russia, CIS countries, Vietnam, Pakistan, and Cuba. Achieving 10 million dollars in finished pharmaceutical exports reflects the internationally recognized superior quality of its products. This achievement affirms Daehan New Pharm’s position as a globally trusted pharmaceutical exporter.

The product is called “Granmectin Pellet”, a type of “Ivermectin Pellet”, developed through“Daehan New Pharm”'s advanced pellet manufacturing technology. It is designed primarily for deworming cattle and pigs, especially in pellet form for ease of administration. The core ingredient is “Ivermectin”, which effectively treats a variety of internal and external parasites in livestock. The pellet form offers advantages such as easy feeding, labor reduction, and minimal stress on animals. Besides the pellets, Daehan New Pharm also offers injectable forms like “Granmectin” and “Granmectin EF”, providing comprehensive parasitic control solutions for farmers. This product exemplifies Daehan New Pharm’s expertise in pellet manufacturing technology, ensuring high efficacy and palatability.

- Sales increased by 32.8% and operating profit increased by 34.0% compared to the same period last year- Poised to receive the 10 Million Dollar Export Tower Award- Bio division started supplying vaccines to domestic animal vaccine manufacturers from April Daehan New Pharm experienced robust growth in the first half of 2015. Cumulative sales for H1 2015 reached 44.095 billion KRW, a 32.8% increase year-over-year, while operating profit rose 34.0% to 4.820 billion KRW. The operating profit margin continued to improve, reaching 10.9%, marking a sustained 15-quarter streak of growth since Q4 2011. Alongside growth, the company reduced accounts receivable by 869 million KRW and borrowings by 598 million KRW compared to the end of 2014. This resulted in 28.3 fewer days in sales receivables turnover and a 7.9 percentage point decrease in the debt-to-sales ratio to 46.8%, indicating strengthened financial stability. Daehan New Pharm has actively implemented operational innovations such as building databases for value-based sales per clinic, disseminating successful case studies, and enhancing sales skills through role-playing. These initiatives are aimed at increasing customer value and talent development, showing positive results in parts. Exports from the overseas business division also showed remarkable growth, with H1 2015 export revenues rising 25.0% year-over-year to 6.068 billion KRW. From July 2014 to June 2015, export sales exceeded 10 million USD, ensuring receipt of the export tower award. The bio division is progressing well with its mid-to-long-term plans, having started regular vaccine supplies to domestic animal vaccine manufacturers since April. Other companies are testing Daehan New Pharm’s vaccines for productivity, safety, and cost-effectiveness to apply them in their production lines. In celebration of its 30th anniversary, Daehan New Pharm engaged its employees in reaffirming their commitment to future growth as a trusted and respected company, while concretizing visions and plans for sustainable long-term development.

Daehan New Pharm has developed the world's first natural herbal ointment containing oregano oil for the treatment of bovine mastitis. The product, named “Ecojet Ointment”, harnesses the anti-inflammatory, antioxidant, antifungal, and antiviral properties of oregano oil—whose major active ingredients, carvacrol and thymol, effectively target mastitis-causing bacteria such as Staphylococcus aureus and E. coli. Confirmed through domestic clinical trials, Ecojet Ointment reduces both pathogenic bacteria and somatic cell counts in milk, offering a patented (Patent No. 10-2015-0020676) and residue-free solution with zero withdrawal period for dairy farmers. In addition to Ecojet Ointment, Daehan New Pharm has introduced a comprehensive mastitis treatment program featuring other products like “Cephalegen” and “Synerjet”. Bovine mastitis is one of the most common diseases in dairy cattle, causing substantial economic losses through increased somatic cell counts, decreased milk quality and yield, especially prevalent during the summer season. Daehan New Pharm’s innovative herbal-based ointment provides an effective and safe alternative to antibiotics, supporting animal health and sustainable dairy production.

- Sales increased by 33.5% and operating profit increased by 37.4% compared to the same period last year. Daehan New Pharm’s strong growth continued into the first quarter of 2015. Q1 2015 sales reached 20.922 billion KRW, growing 33.5% year-over-year, and operating profit rose 37.4% to 2.261 billion KRW, marking a strong start to 2015. This growth reflects the company’s transformation into a cash flow–centric business model, resulting in a positive cash balance. Increased brand recognition and trust, combined with talent-focused management, have enhanced Daehan New Pharm’s unique appeal. Daehan New Pharm has committed 2015 as a year of breakthrough growth and innovation. The company is focusing on discovering future growth drivers, exploring exclusive niche markets, developing market-leading products, and driving creative growth through tailored sales solutions. Its goal is to build a balanced and solid growth foundation by optimizing the product portfolio, securing investment resources through self-sustaining operations, and strengthening core competencies. To become an opportunity-seeking, leading organization, Daehan New Pharm is strengthening collaborative innovation with pioneering veterinarians, forging industry-academia partnerships, and building networks with key specialists to enhance open innovation. It is also reviewing efficient research systems to clarify its vision and establish a robust product pipeline. The company is bolstering its development and research talent and operates a cross-functional development committee linking development, production, marketing, and sales teams. These efforts aim to enhance customer satisfaction and seize growth opportunities. While 2014 focused on driving value innovation, 2015 is poised to elevate this innovation to a new level. All employees are dedicating creative effort to foster synergies through connection and collaboration, aiming for a strategically significant year of growth and success.

- Sales up 26.9% and operating profit up 32.6% year-on-year- Expansion of injectable product line and completion of production facilities for animal cell culture media- Exports to Russia up 47% Daehan New Pharm continues its strong growth trend.In 2014, the company achieved sales of 71.94 billion KRW, a 26.9% increase from the previous year, and operating profit of 7.91 billion KRW, up 32.6%, marking its third consecutive year of remarkable growth. Furthermore, as cash flow-oriented management became established across all departments, borrowings and accounts receivable decreased, leading to an improved financial structure. Daehan New Pharm operates three key business divisions: the pharmaceutical business (its core segment), the veterinary medicine business (its foundational segment), and the bio business, which is being driven as a future growth engine. All divisions achieved double-digit growth last year, making it a significant year for the company. In the pharmaceutical business, strong performance was driven by continuous growth and market leadership in the “Well-being” division through The Only Product strategy, innovation in distribution channels by directly managing hospitals and clinics, and strengthening the distribution network through customer asset acquisition. Ongoing new product launches created an optimized portfolio, enhancing sales synergy. The company also improved organizational productivity and internal capabilities through talent management that fosters and develops core professionals. Export performance in pharmaceuticals has also been notable. Overseas exports, a source of pride for Daehan New Pharm, have steadily grown. In 2014, exports exceeded 10 billion KRW, with exports to Russia alone reaching USD 3.2 million — a 47% year-on-year increase for a single product. The veterinary medicine business has strengthened customer satisfaction through customized product development and continues to cooperate with local governments and organizations to develop new products. As for the bio business, regarded as the company’s future growth driver, Daehan New Pharm completed a new factory for animal cell culture media in April last year and began supplying domestically produced media from the third quarter. As the company gained recognition for quality following testing, its client base expanded. Through industry-academia collaboration, it is also engaging in R&D to introduce a new paradigm in cell proliferation.

Daehan New Pharm continues to broaden its growth momentum through consistent sales expansion of its core products. - Sales up 24.4% and operating profit up 43.4% year-on-year- Expansion of injectable production lines to meet market demand- Full-scale operation of the cell culture media production line Daehan New Pharm’s growth trajectory is accelerating. In 2014, the company recorded cumulative sales of 51.93 billion KRW, up 24.4% from the same period of the previous year; operating profit reached 5.86 billion KRW, a 43.4% increase; and ordinary profit rose by 117% to 3.62 billion KRW. For the third quarter alone, sales increased 28.8% and operating profit jumped 49% year-on-year, maintaining solid growth every quarter. As a result, the company’s debt-to-sales ratio improved by 18.2 percentage points, and days sales outstanding (DSO) were reduced by 55 days. Notably, both sales and operating profit are gaining growth momentum compared to the previous year, alongside continued improvement in financial soundness and operational stability. Guided by its corporate mission of contributing to a healthy life, a happy society, and a sense of warmth, Daehan New Pharm is continuously creating value innovation through a focus on fundamentals, strengthening of core competencies, cash flow-oriented management, proactive risk control, launch of leading products, expansion of distribution coverage through creative solution-based sales, and human-centered management. To further foster growth in the wellness business segment, the company completed construction of its new injectable production line, enabling stable supply of ampule and vial injections to meet increasing market demand. Meanwhile, to secure future growth drivers, it has completed a facility capable of producing 350,000 liters per month of cell culture media during the first half of the year. The plant has now entered full-scale operation with sales, production, and R&D activities underway, and began supplying domestically produced media to bio companies from the third quarter.

Sustained Growth in the First Half of 2014 - Sales up 20.4% and operating profit up 39.8% year-on-year- Rapid improvement of financial structure- Expansion and strengthening of the pharmaceutical local and wholesale divisions- Completion of bio media plant construction Daehan New Pharm’s growth momentum continued strongly into the first quarter of 2014. The company recorded total first-quarter sales of 15.67 billion KRW, representing a 20.4% increase compared to the same period last year. Operating profit reached 1.65 billion KRW, up 39.8%, and ordinary profit rose 83.7% to 1.12 billion KRW, demonstrating robust growth and profitability. By focusing on its core business areas and pursuing profit- and cash flow-centered management, Daehan New Pharm has enhanced business structure quality and growth sustainability. With shorter receivable turnover periods and reduced borrowings, its financial structure continues to improve rapidly. The company’s growth is also being propelled by strengthened leadership in the wellness and beauty sector through differentiated obesity solutions, alongside innovation in distribution structures managing hospitals and clinics directly to secure customer assets and reinforce its distribution network. To further strengthen its distribution network for sustainable growth, Daehan New Pharm expanded and reorganized its pharmaceutical local and wholesale divisions into independent business units as of March 1. The local division, focused on wellness products, is building relationships with hospitals and clinics, positioning the company as a leading player in this segment. The wholesale division aims to generate synergy with the local division by developing wholesale-exclusive products and nurturing key distributors, evolving into a "Company in Company" model within Daehan New Pharm. In addition, Daehan New Pharm has completed construction of its bio media plant, establishing a full-scale production system. Test production will be finalized in the second quarter of 2014, after which the company plans to supply customized bio media to clients. Moving forward, Daehan New Pharm will focus on fostering core media and bioprocess products—its next-generation growth engines—laying the foundation for advancement into a leading small-to-mid-sized global biotech company.